Results 191 to 200 of about 27,465 (289)

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Megalomyrmex milenae Transcriptome Reveals a Complex Venom Cocktail. [PDF]

Toxins (Basel)
Sozanski KS, Coelho GR, Ishihara MA, Delgado A, Adams RMM.   +4 more
europepmc   +1 more source

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Balinatunfib is the first oral, small molecule selective inhibitor of TNFR1 signaling. The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe adverse events in patients with mild‐to‐moderate psoriasis and showed clinical responses.
Nassr Nassr, Ohn A. Chow, Mai Anh Nguyen, Laurent Perrin, Fabienne Schumacher, Frank‐Dietrich Wagner, Caroline Dreis, Amel Lahmar, Markus Kohlmann, Maria Wiekowski, Tiago R. Matos   +10 more
wiley   +1 more source

In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia. [PDF]

Clin Psychopharmacol Neurosci
Barbagallo F, Assenza MR, Messina A.
europepmc   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models. [PDF]

J Clin Invest
Kim J, Yoon H, Joe SC, Smith A, Park J, Hong G, Ha JM, Kim EB, Seki E, Kim MK, Lee HO, Kim HS, Chung JH.   +12 more
europepmc   +1 more source

Engineering the bacterial nutrition strategy to control plant diseases

Journal of Integrative Plant Biology, EarlyView.
This commentary on Wang et al. (2025) and Phan et al. (2025) highlights previously undiscovered Xanthomonas pathways for nutrition acquisition, explains how Xanthomonas bacteria hijack host molecular machinery through their effector proteins, and discusses how these studies can be used to develop new disease resistance mechanisms.
Muhammad Arslan Mahmood, Shahid Mansoor, Muhammad Naveed Aslam   +2 more
wiley   +1 more source

Targeted Alkaline Phosphatase Therapy Enhances Alveolar Bone Healing in X‐Linked Hypophosphatemia in Mice

Journal of Periodontal Research, EarlyView.
Effects of exogenous tissue‐nonspecific alkaline phosphatase (TNAP) were analyzed in the Hyp mouse model of X‐linked hypophosphatemia (XLH). Maxillary first molars were extracted from wild‐type (WT) and Hyp mice at 6 weeks, and collagen gel ± TNAP was placed in sockets. In one group of Hyp mice, submucosal injections of TNAP or saline were delivered at
Aonjittra Phanrungsuwan, Bella Donnelly, José Luis Millán, Brian L. Foster   +3 more
wiley   +1 more source

Protein Kinase A Signaling in Cortisol Production and Adrenal Cushing's Syndrome. [PDF]

Cells
Kumar A, Sharma A, Omar MH.
europepmc   +1 more source

Krisanaklan Reduces Intestinal Anion and Fluid Secretion Through Inhibition of Na+/K+‐ATPase and K+ Channel Activity

Annals of the New York Academy of Sciences, EarlyView.
Krisanaklan reduces CFTR‐dependent intestinal chloride and fluid secretion by inhibiting the Na+,K+‐ATPase and K+ channels in epithelial cells. Consequently, this natural, plant‐derived product may limit secretory diarrhea caused by a diverse array of microbial pathogens. However, by dissipating the transmembrane Na+ gradient, Krisanaklan also inhibits
Tessa A. Groeneweg, Erdene Baigal, Anny Leung, Gert‐Jan Kremers, Marcel J. C. Bijvelds   +4 more
wiley   +1 more source